ArticleCell death discovery2026
Comparative phenotypic and molecular profiling of replicative and chemically-induced senescence in articular chondrocytes.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual-modal antioxidant and epigenetic synergy attenuates the self-perpetuating senescence cycle in osteoarthritis.Bioactive materials · 2027Article
- Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.Bioactive materials · 2027Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by the accumulation of senescent chondrocytes, which drive inflammation and cartilage degradation. However, in vitro models often fail to recapitulate the complexity of OA-associated senescence. This study compares three senescence induction strategies in chondrocytes-replicative senescence (HP), and stress-induced premature senescence (SIPS) via doxorubicin (DOX) and dexamethasone (DEX)-to establish a physiologically relevant in vitro model for OA research. To this end ovine chondrocytes (n = 3) were subjected to serial passaging (to P40) or exposed to optimized concentrations of DOX (50 nM) or DEX (1 µM). Low passage (P3) cells served as controls. Cellular senescence was assessed via proliferation assays, cell cycle analysis, SA-β-gal activity, telomere length, ROS levels, mitochondrial function, transcriptomic profiling (NGS), and high-resolution mass spectrometry proteomic analysis. All models induced key senescence hallmarks including cell cycle and proliferation arrest, increased SA-β-gal activity, and mitochondrial dysfunction. HP cells showed telomere shortening, ROS accumulation, ATP depletion, and SASP secretion. DOX induced strong DNA damage responses and elevated apoptosis markers, while DEX induced senescence without significant ROS or apoptosis, suggesting distinct SIPS mechanisms. Transcriptomics revealed convergent downregulation of oxidative phosphorylation and selenoamino acid metabolism pathways, implicating mitochondrial dysfunction and redox imbalance as shared features. However, HP induced broad transcriptional suppression, also of inflammatory pathways, while DOX and DEX activated immune and SASP-related pathways. Proteomics confirmed divergent secretory profiles, with DOX/DEX increasing SASP-factors and HP enriching matrix proteins. In summary, although all models recapitulate fundamental aspects of senescence, they diverge in stress responses, immune signaling, and apoptosis profiles. HP most closely mimics aging-associated senescence, whereas DOX and DEX model distinct SIPS relevant to oxidative or pharmacological stress. These findings underscore the importance of model selection in senescence-focused OA research and highlight mitochondrial dysfunction as a central mechanistic hub across senescence pathways.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.